Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16062033 | 0.98 | IDO1 (0.63) | IDO1CYP11B1CYP11B2HPGDMEN1 | |
| SCHEMBL22922181 | 0.90 | CYP4F2 (0.59) | IDO1KMT2ACYP4F2CYP4A11POLB | |
| SCHEMBL1858237 | 0.89 | IDO1 (0.55) | IDO1CYP11B1CYP11B2HPGDMEN1 | |
| SCHEMBL2828491 | 0.87 | FFAR1 (0.71) | IDO1MEN1KMT2AFFAR1FFAR4 | |
| SCHEMBL17593254 | 0.87 | IDO1 (0.53) | IDO1CYP11B1CYP11B2HPGDMEN1 | |
| SCHEMBL14680583 | 0.85 | IDO1 (0.52) | IDO1CYP11B1CYP11B2HPGDMEN1 | |
| SCHEMBL11887474 | 0.85 | IDO1 (0.52) | IDO1CYP11B1CYP11B2HPGDMEN1 | |
| SCHEMBL8879639 | 0.85 | CYP4F2 (0.50) | IDO1CYP11B1CYP11B2KMT2ACYP4F2 | |
| SCHEMBL1483117 | 0.85 | CYP4F2 (0.50) | IDO1CYP11B1CYP11B2KMT2ACYP4F2 | |
| SCHEMBL18455229 | 0.84 | IDO1 (0.51) | IDO1CYP11B1CYP11B2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250075079-A1 | POLYMERIC FLUOROPHORES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF PREPARING AND USING THE SAME | UNIV NORTH CAROLINA STATE (US) | 2025-03-06 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4469441-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | Parion Sciences, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12139617-B2 | Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same | NORTH CAROLINA STATE UNIVERSITY (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20090088368-A1 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2009-04-02 | — | — | US | disclosed |
| US-20090088368-A1 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2009-04-02 | — | — | US | disclosed |
| EP-1979360-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| CN-100376242-C | 2-aryl-propionic acid and medicine composition containing same | DOMPAY CO LTD (IT) | 2008-03-26 | — | — | CN | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| WO-2007089667-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| CN-1839114-A | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | CN | disclosed |
| CN-1612729-A | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPAY CO LTD (IT) | 2005-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | IDO1 3764/4885CYP11B1 354/4885CYP11B2 351/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | IDO1 1614/4885CYP11B1 226/4885CYP11B2 370/4885 |
| US-20250075079-A1 | POLYMERIC FLUOROPHORES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF PREPARING AND USING THE SAME | CLTB, PAICS, HLCS | IDO1 3732/4885CYP11B1 3759/4885CYP11B2 4151/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | IDO1 1175/4885CYP11B1 525/4885CYP11B2 599/4885 |
| US-12139617-B2 | Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same | CLTB, PAICS, HLCS | IDO1 3732/4885CYP11B1 3759/4885CYP11B2 4151/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | IDO1 1007/4885CYP11B1 173/4885CYP11B2 205/4885 |
| US-20090088368-A1 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | PPARG, PPARA, PPARD | IDO1 4548/4885CYP11B1 403/4885CYP11B2 576/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | IDO1 1421/4885CYP11B1 71/4885CYP11B2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.